How Market Research Helps Organizations Understand the US Health System Landscape

A practical guide for healthcare executives, payers, pharma companies, and health system strategists.

Key Takeaways

• The US health system is one of the most complex in the world — fragmented, multi-payer, and constantly evolving.
• Organizations that rely on generic data sources routinely underestimate the local and regional variation that drives real decision-making.
• Specialist primary research reveals how payers, providers, patients, and policymakers actually behave — not just what industry reports say they do.
• Phronesis Partners designs bespoke research programmes that map stakeholder dynamics, policy impact, and competitive positioning across the US health landscape.
• Market research is not a cost — it is a risk management tool that protects strategy, investment, and product launch decisions.

Why the US Health System Demands Specialist Research

No healthcare market in the world rewards generic research less than the United States.

With over 900 health systems, more than 5,000 hospitals, multiple competing payer models, and a regulatory environment that shifts with every legislative cycle, the US health system is structurally resistant to broad generalizations. What is true in Massachusetts is often not true in Texas. What works for a commercial insurer may be entirely irrelevant for a Medicaid managed care organization.

For any organization trying to enter, compete, or grow within this landscape — whether a global pharma company, a medtech provider, a health system looking to benchmark, or a private equity firm evaluating an acquisition — the quality of your market intelligence is a direct determinant of the quality of your strategy.

At Phronesis Partners, we have conducted research across the full spectrum of the US health system. What we consistently find is that the decisions that drive real outcomes — formulary placement, network inclusion, contract terms, capital allocation — are shaped by stakeholder relationships, institutional priorities, and local market dynamics that only primary research can reliably surface.

What Does the US Health System Landscape Actually Look Like?

Before designing a research programme, it is worth being precise about what ‘the US health system’ actually comprises. It is not a single entity — it is an interconnected set of markets, each with its own logic.

The Four Research Questions That Matter Most

In our experience working with organizations across the US health system, most research needs cluster around four fundamental questions. Each requires a different methodological approach.

1. Who are the real decision-makers?

Formal organizational charts rarely reflect how health system decisions actually get made. A CMO may have nominal authority over technology adoption, but the decision is driven by a Value Analysis Committee. A formulary decision involves medical, pharmacy, and finance functions simultaneously. Primary research — in-depth interviews with actual decision-makers and their influencers — is the only reliable way to map these dynamics.

2. What do stakeholders actually value?

Payers and providers consistently say they prioritise clinical outcomes and patient experience. They frequently make decisions based on unit cost, administrative simplicity, and relationship history. Conjoint analysis and scenario-based research designs reveal what stakeholders genuinely trade off when it matters — not what they report in general surveys.

3. How does this market vary by geography?

The US is not one healthcare market. A Blue Cross Blue Shield plan in Michigan operates under entirely different dynamics from a regional health plan in California. A Midwestern community hospital faces a fundamentally different competitive environment from an academic medical centre in Boston. Research that does not account for regional variation produces findings that are true on average and wrong in every specific market.

4. Where is the market heading?

The US health system is in a period of accelerating structural change — value-based care models are maturing, consolidation among both providers and payers is continuing, and the role of technology in care delivery is expanding faster than most organizations can track. Horizon scanning and expert network research help organizations anticipate change rather than react to it.

How Phronesis Partners Approaches US Health System Research

Our methodology is built around one principle: insight should be actionable. That means designing research that answers the specific questions your organization needs to act on — not producing generalized landscape reports that describe trends you already know.

Quantitative Research

We design structured surveys with statistically robust samples drawn from our proprietary panel of US healthcare professionals, executives, and administrators. Our quantitative programmes use:

• Conjoint and discrete choice analysis — to reveal true preference hierarchies among payers, providers, and prescribers.
• Driver analysis — to distinguish between factors that correlate with positive outcomes and those that cause them.
• Segmentation modelling — to identify meaningfully distinct stakeholder groups with different needs and priorities.
• Benchmarking surveys — to compare performance, satisfaction, and perception against sector norms.

Qualitative Research

Numbers tell you what is happening. In-depth interviews and expert discussions tell you why. Our qualitative programmes engage C-suite executives, medical directors, formulary decision-makers, and policy influencers directly — producing the nuanced, contextualized insight that quantitative data alone cannot deliver.

Secondary Research and Landscape Mapping

We complement primary research with rigorous secondary analysis — synthesising CMS data, state-level health policy developments, peer-reviewed literature, and competitive intelligence to provide the structural context that makes primary findings interpretable.

Who Benefits From US Health System Market Research?

The need for specialist health system intelligence cuts across sectors. The table below identifies the most common client types and their primary research requirements.

Making the Case for Primary Research Over Secondary Data

Secondary data sources — CMS claims data, IQVIA reports, Advisory Board publications — are valuable for understanding the macro landscape. They tell you how many lives a plan covers, what a drug’s market share is, or how hospital consolidation is trending nationally.

What they cannot tell you is why a specific health system is choosing one technology vendor over another, what a regional payer’s formulary committee is actually prioritizing in the next contract cycle, or how a new CMS reimbursement model is being interpreted by providers on the ground.

That level of specificity only comes from primary research. And in a market where the difference between getting the decision right and wrong can mean hundreds of millions of dollars in product revenue, formulary exclusion, or a failed acquisition, the investment in primary intelligence is straightforwardly justified.

Frequently Asked Questions

What is US health system market research?

US health system market research is the systematic collection and analysis of data about the stakeholders, structures, and dynamics that shape healthcare delivery, purchasing, and policy in the United States. It encompasses payer and provider research, patient and HCP studies, competitive intelligence, and policy impact analysis.

Why is specialist research needed for the US health system?

The US health system is highly fragmented, with significant variation by payer type, geography, and care setting. Generic industry reports provide useful macro context but lack the specificity needed for competitive strategy, market access planning, or investment decisions. Specialist primary research is designed around the specific questions your organisation needs answered, with the right respondents and methodologies.

What types of organizations use health system market research?

Pharmaceutical and biotech companies use it for market access and launch strategy. MedTech firms use it to understand clinical adoption barriers. Health systems commission it for competitive benchmarking. Payers use it for member and employer research. Private equity and strategic investors use it for due diligence and market sizing. Management consultancies use it to underpin client strategy work.

How does Phronesis Partners access US healthcare decision-makers?

Phronesis Partners maintains a proprietary panel of senior healthcare professionals, executives, and administrators across the United States — including C-suite leaders, medical directors, formulary committee members, and health system procurement teams. This direct access enables us to field research with relevant, senior respondents rather than relying on general consumer panels.

How long does a US health system research project typically take?

Project timelines depend on scope, methodology, and target respondent profile. A focused quantitative study typically takes four to six weeks from briefing to final report. A combined quantitative and qualitative programme, or one requiring a particularly specialist respondent profile, typically takes eight to twelve weeks. We discuss timelines and critical decision points at the outset of every engagement.